Fred Ramsdell

Fred Ramsdell is a 2025 Nobel Laureate in Physiology or Medicine and one of the world’s foremost molecular immunologists, whose decades-long career bridging basic science and biotechnology produced one of the most consequential genetic discoveries in the history of medicine. Trained at UC San Diego and UCLA, where he earned his PhD in microbiology and immunology in 1987 under the mentorship of Sidney Golub, Ramsdell went on to a fellowship at the National Institutes of Health before embarking on an industry research career that would span more than three decades across some of the most influential biotech institutions in the United States.

Nobel Prize speaker Fred Ramsdell is best known for co-discovering FOXP3 — the master transcription factor governing the development and function of regulatory T cells, the immune system’s primary mechanism for preventing attacks on the body’s own tissues. Working alongside Mary Brunkow at Darwin Molecular and later Celltech in Bothell, Washington, Ramsdell led the immunology program that identified a critical mutation in the “scurfy” mouse strain, tracing it to a previously unknown gene they named FOXP3. Their three landmark papers in Nature Genetics in 2001 established FOXP3 as the molecular key to immune self-tolerance and demonstrated that mutations in the human equivalent cause IPEX syndrome, a devastating and often fatal autoimmune disorder. The discoveries directly enabled Shimon Sakaguchi’s subsequent proof that FOXP3 governs the regulatory T cells he had identified in 1995 — completing a body of work that launched an entirely new field in immunology.

From Bench to Clinic: A Career Defined by Translation

Ramsdell’s career is distinguished not only by the depth of his foundational discoveries but by his sustained commitment to turning them into therapies. Following Celltech, he held research leadership roles at ZymoGenetics and Novo Nordisk, where he helped establish the company’s Inflammation Research Center in Seattle. He then served as Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy, building and advancing multiple oncology research programs from the ground up. He is a co-founder of Sonoma Biotherapeutics, a clinical-stage biotech developing engineered Treg cell therapies for serious autoimmune and inflammatory diseases, where he serves as Scientific Advisory Board Chair. In 2017, he shared the Crafoord Prize — one of science’s most prestigious honors — alongside Shimon Sakaguchi and Alexander Rudensky for their work on regulatory T cells. His Nobel-recognized research has helped catalyze more than 200 active clinical trials worldwide across cancer, autoimmunity, and transplantation.

As a speaker, Fred Ramsdell brings to the stage a career-long perspective on how rigorous basic science becomes world-changing medicine. From the early puzzle of a mutant mouse strain to a Nobel Prize announced while he was off the grid hiking in the Rockies, his story is one of deep intellectual curiosity, resilience, and the extraordinary long-term payoff of foundational research. Audiences in biotech, pharma, healthcare, and innovation leadership gain a rare inside view of how discovery actually happens — and why investing in fundamental science remains the most powerful lever for human health.